Biosynth, a developer and supplier of critical raw materials and services for life sciences and diagnostics, has opened an expanded GMP bioconjugation facility at its existing Berlin site. This strategic expansion significantly enhances Biosynth’s specialized manufacturing capabilities in conjugate vaccines and conjugate drugs, activated PEGs, and polymer-based drug delivery excipients as part of its global manufacturing network. Thomas Eisele, COO, stated, “We are thrilled to ...